WO1998058956A3 - Methods for inducing an immune response involving prime-boost protocols - Google Patents

Methods for inducing an immune response involving prime-boost protocols Download PDF

Info

Publication number
WO1998058956A3
WO1998058956A3 PCT/US1998/012894 US9812894W WO9858956A3 WO 1998058956 A3 WO1998058956 A3 WO 1998058956A3 US 9812894 W US9812894 W US 9812894W WO 9858956 A3 WO9858956 A3 WO 9858956A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
immune response
inducing
response involving
boost protocols
Prior art date
Application number
PCT/US1998/012894
Other languages
French (fr)
Other versions
WO1998058956A2 (en
Inventor
Guy Warnier
Catherine Uyttenhove
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Priority to AU79831/98A priority Critical patent/AU7983198A/en
Publication of WO1998058956A2 publication Critical patent/WO1998058956A2/en
Publication of WO1998058956A3 publication Critical patent/WO1998058956A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This invention relates to improved methods for modulating an immune response against an antigen using adenoviruses which express the antigen for priming immunization and antigen peptides for booster immunizations. Preferably the peptides are combined with QS21/MPL adjuvant. In particular, immunization methods for tumor antigens are provided. Kits for immunization are also provided.
PCT/US1998/012894 1997-06-23 1998-06-19 Methods for inducing an immune response involving prime-boost protocols WO1998058956A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU79831/98A AU7983198A (en) 1997-06-23 1998-06-19 Improved methods for inducing an immune response

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88097997A 1997-06-23 1997-06-23
US08/880,979 1997-06-23

Publications (2)

Publication Number Publication Date
WO1998058956A2 WO1998058956A2 (en) 1998-12-30
WO1998058956A3 true WO1998058956A3 (en) 1999-03-18

Family

ID=25377532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/012894 WO1998058956A2 (en) 1997-06-23 1998-06-19 Methods for inducing an immune response involving prime-boost protocols

Country Status (3)

Country Link
AU (1) AU7983198A (en)
WO (1) WO1998058956A2 (en)
ZA (1) ZA985460B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265215B1 (en) * 1996-09-13 2001-07-24 Ludwig Institute For Cancer Research Isolated peptides which complex with HLA-Cw16 and uses thereof
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
CA2388337C (en) 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
DE10112851C1 (en) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogeneic anti-tumor vaccine with HLA-haplo-identical antigen-presenting cells
WO2003050268A2 (en) 2001-12-12 2003-06-19 Aventis Pasteur Limited Enhancement of the immune response using cd36-binding domain
EP2246067B1 (en) * 2003-06-17 2017-02-15 MannKind Corporation Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposes
US20050287068A1 (en) * 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
JP2008526763A (en) * 2004-12-29 2008-07-24 マンカインド コーポレイション Methods for inducing, enhancing and retaining immune responses against MHC class I restricted epitopes for prophylactic or therapeutic purposes
US7338670B2 (en) 2005-04-14 2008-03-04 Duke University Use of an agent that restores tissue perfusion and oxygenation
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2468300T3 (en) 2006-09-26 2018-04-30 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
ES2725450T3 (en) 2007-07-02 2019-09-24 Etubics Corp Methods and compositions for the production of an adenoviral vector for use in multiple vaccinations
US8697854B2 (en) 2008-11-24 2014-04-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh High affinity T cell receptor and use thereof
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
ES2787455T3 (en) 2012-05-16 2020-10-16 Immune Design Corp HSV-2 vaccines
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
US8957047B2 (en) 2013-04-18 2015-02-17 Immune Design Corp. GLA monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
MA47016A (en) 2015-10-22 2018-08-29 Modernatx Inc RESPIRATORY VIRUS VACCINES
MA50335A (en) 2016-12-08 2020-08-19 Modernatx Inc NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUSES
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRANCHINI ET AL: "Highly Attenuated HIV Type 2 Recombinant Poxviruses, but Not HIV-2 Recombinant Salmonella Vaccines, Induce Long-Lasting Protection in Rhesus Macaques", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 11, 1995, pages 909 - 920, XP002079473 *
PIALOUX ET AL: "A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI)", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 11, 1995, pages 373 - 381, XP002079474 *
WARNIER G ET AL: "Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A.", INTERNATIONAL JOURNAL OF CANCER, (1996 JUL 17) 67 (2) 303-10. JOURNAL CODE: GQU. ISSN: 0020-7136., UNITED STATES, XP002079472 *
ZHAI Y ET AL: "Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.", JOURNAL OF IMMUNOTHERAPY, (1997 JAN) 20 (1) 15-25. JOURNAL CODE: CUQ., UNITED STATES, XP002036182 *

Also Published As

Publication number Publication date
AU7983198A (en) 1999-01-04
WO1998058956A2 (en) 1998-12-30
ZA985460B (en) 1999-01-26

Similar Documents

Publication Publication Date Title
WO1998058956A3 (en) Methods for inducing an immune response involving prime-boost protocols
EP1335023A3 (en) Methods and reagents for vaccination which generate a CD8 T cell immune response
WO1998037095A3 (en) Recombinant pox virus for immunization against muc1 tumor-associated antigen
WO2000067761A8 (en) Compositions and methods for identifying antigens which elicit an immune response
EP1847549A3 (en) Papillomavirus polyprotein constructs
WO1995029193A3 (en) Melanoma antigens
WO2001034801A3 (en) Recombinant gelatin in vaccines
WO2000029428A3 (en) 5t4 tumour-associated antigen for use in tumour immunotherapy
WO2002080851A3 (en) Chimeric vaccines
WO2001082963A3 (en) Method of identifying and producing antigen peptides and use thereof as vaccines
CA2259140A1 (en) Method of activating dendritic cells
DK0835133T3 (en) Recombinant smallpox virus rabies and combination preparations and their uses
WO1989001973A3 (en) Recombinant pox virus for immunization against tumor-associated antigens
IS4518A (en) New vaccine formulation
WO2000054802A3 (en) Method of expressing antigens on the surface of antigen presenting cells by photochemical internalization
WO2002034205A3 (en) Using heat shock proteins to increase immune response
IL126803A0 (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
WO2003011331A3 (en) Materials and methods relating to improved vaccination strategies
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
WO2000012122A3 (en) Low-molecular fragments of hyaluronic acid for the preparation of vaccines
WO1999002132A3 (en) Use of submicron oil-in-water emulsions with dna vaccines
WO2000063385A3 (en) Nucleic acid immunization
CO5280140A1 (en) ANTIGEN (C42) ASSOCIATED WITH TUMORS
WO2000063242A8 (en) Chimeric lyssavirus nucleic acids and polypeptides
WO2002070004A3 (en) Papillomavirus vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN JP KR NZ

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1999504909

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA